

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
HIGHLY SPECIALISED TECHNOLOGIES EVALUATION PROGRAMME

Equality impact assessment – Scoping

HST Onasemnogene abeparvovec for treating spinal muscular atrophy type 1

Batch 63

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultees highlighted that, because onasemnogene abeparvovec would be provided at a limited number of highly specialist centres, there was the potential for issues of equity of access based on geographic location.

Consultees commented that using spinal muscular atrophy (SMA) 'type' to define the population may be inappropriate and could lead to discrimination on the basis of a particular disability.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Access to highly specialist centres is an implementation issue; it is not an equality issue to be considered by the committee, and cannot be addressed in technology appraisal guidance.

This evaluation will consider the technology for treating spinal muscular atrophy type 1, within its marketing authorisation. If appropriate, the committee may give consideration to the impact of disability on its methods and considerations during the evaluation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?
No changes to the scope are needed.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No changes to the matrix are needed.

Approved by Associate Director (name):Sheela Upadhyaya

Date: 06/06/2019